SCHEMBL30765706

SCHEMBL30765706

COc1ccc(CCCNc2cnc(-c3ccccc3)n(CC(=O)O)c2=O)cc1

nearest known ligand 0.47

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ELANE P08246 3/20 0.47
ALDH1A1 P00352 2/20 0.43
LMNA P02545 1/20 0.43
KDM4E B2RXH2 1/20 0.43
HPGD P15428 1/20 0.43
ALOX15 P16050 1/20 0.43
HTT P42858 1/20 0.43
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
EGLN1 Q9GZT9 1/20 0.41
ACP1 P24666 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765501 0.92 ELANE (0.44) ELANEALDH1A1LMNAKDM4EHPGD
SCHEMBL30766097 0.90 ASPH (0.49) ELANEKDM4EHPGDEGLN1
SCHEMBL30766150 0.89 GAA (0.52) ELANEALDH1A1LMNAKDM4EHPGD
SCHEMBL23461187 0.83 KDM4E (0.47) ELANEKDM4E
SCHEMBL30766006 0.82 KDM4E (0.42) ELANEKDM4EEGLN1
SCHEMBL30765807 0.82 CASP1 (0.47) ELANELMNA
SCHEMBL30766118 0.82 ELANE (0.41) ELANEKDM4E
SCHEMBL30765659 0.81 ELANE (0.39) ELANEKDM4ENPC1RAB9AEGLN1
SCHEMBL30765994 0.81 ELANE (0.46) ELANEALDH1A1KDM4EEGLN1
SCHEMBL6799310 0.80 RAB9A (0.54) ELANEALDH1A1LMNAKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed